<DOC>
	<DOCNO>NCT02528253</DOCNO>
	<brief_summary>This study investigate efficacy safety tanezumab 5 mg 10 mg administer subcutaneous injection seven time 8 week interval ( 56 week ) . The primary objective study evaluate effectiveness tanezumab 10 mg 5 mg compare placebo treatment chronic low back pain . Secondary objective evaluate long-term safety effectiveness tanezumab 10 mg 5 mg compare placebo treatment chronic low back pain . In addition , study evaluate effectiveness long term safety profile tanezumab treatment chronic low back pain compare tramadol Prolonged Release ( PR ) , medication commonly utilized treatment chronic low back pain .</brief_summary>
	<brief_title>A Phase 3 Study Tanezumab Chronic Low Back Pain</brief_title>
	<detailed_description>This randomize , double blind , placebo active control , multicenter , parallel group Phase 3 study efficacy safety tanezumab administer SC injection 56 week subject chronic low back pain . Approximately 1800 subject randomize 1 4 treatment group 2:2:2:3 ratio ( ie , 400 subject per treatment group placebo , tanezumab 5 mg tanezumab 10 mg treatment group 600 subject tramadol PR treatment group ) . Treatment group include : 1 . ) Placebo administer SC 8 week interval plus placebo matching tramadol PR Week 16 . At Week 16 visit , subject group meet efficacy responder criterion switch blinded fashion 1:1 ratio either tanezumab 5 mg tanezumab 10 mg administer SC 8 week interval plus placebo matching tramadol PR Week 56 ; 2 . ) Tanezumab 5 mg SC administer 8 week interval plus placebo matching tramadol PR Week 56 ; 3 . ) Tanezumab 10 mg SC administer 8 week interval plus placebo matching tramadol PR Week 56 ; 4 . ) Oral tramadol PR plus placebo administer SC 8 week interval Week 56 . The study design total duration ( post randomization ) 80 week consist three period : Screening ( maximum 37 day ; include Washout Period Initial Pain Assessment Period ) , Double blind Treatment Period ( comprise 16 week Primary Efficacy Phase 40 week Long Term Safety Efficacy Phase ) , Follow Period ( 24 week ) . The Screening Period ( begin 37 day prior Randomization ) include Washout Period ( last 2 32 day ) , require , Initial Pain Assessment Period ( 5 day prior Randomization/Baseline ) . Prior enter study , subject must document history previous inadequate treatment response medication 3 different category agent commonly use treat generally consider effective treatment chronic low back pain .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Chronic low back pain â‰¥3 month duration , Quebec Task Force Spinal Disorders class 1 2 , document history previous inadequate treatment response least 3 different category agent commonly use generally consider effective treatment chronic low back pain . Diagnosis osteoarthritis knee hip define American College Rheumatology ( ACR ) criterion . Subjects Kellgren Lawrence Grade &gt; =2 radiographic evidence hip Grade &gt; or=3 radiographic evidence knee osteoarthritis exclude ; History radiographic evidence disease could confound efficacy safety assessment ( e.g. , rheumatoid arthritis ) . History radiographic evidence orthopedic condition may increase risk , confound assessment joint safety condition study . Signs symptom clinically significant cardiac disease within 6 month study ( e.g. , unstable angina , myocardial infarction , rest bradycardia , poorly control untreated hypertension ) define protocol subject cardiovascular illness opinion Investigator would render subject unsuitable participate study History , diagnosis , sign symptom clinically significant neurological disease ( e.g. , transient ischemic attack , stroke , peripheral autonomic neuropathy ) specify protocol Subjects evidence symptom consistent autonomic dysfunction ( e.g. , orthostatic hypotension and/or autonomic symptom ) define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic low back pain</keyword>
	<keyword>Chronic pain</keyword>
</DOC>